Soheil Madadi

TL;DR: This article focuses on recent advances made within the last 5 years in nanoparticle‐based cancer immunotherapy, including peptide‐ and nucleic acid‐based nanovaccines, nanomedicines containing an immunoadjuvant to activate anti‐tumor immunity, nanoparticle delivery of immune checkpoint inhibitors and the combination of the above approaches.

TL;DR: An overview on microRNAs that are involved in the Aβ cascade and their inhibitory impact on their target mRNAs whose products participate in Aβ clearance is discussed.

TL;DR: The analysis shows, among others, that RNU6 is not an ideal normalizer in studies using patient material from different diseases, and the urgent need for the identification of suitable reference controls to produce reliable data is highlighted.

TL;DR: The current state-of-the-art in BC angiogenesis-mediated by angioregulatory miRNAs is described, and an overview of mi RNAs dysregulation association with the anti-angiogenic response in addition to potential clinical application of miRN as-based therapeutics are described.

TL;DR: It is found that miR-106b was significantly down-regulated in the serum samples of AD patients compared with those of controls, suggesting it might be a promising serum biomarker for early diagnosis of AD.